Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OCTRU is running a one-day course for those wishing to be a chief investigator on the design and conduct of clinical trials on Friday 10th June 2016 at the Botnar Research Centre.

The Oxford skyline

Aim: To provide those wishing to be a chief investigator with a greater understanding of how to design and conduct their own clinical trial and the secrets of a successful funding application.

 

Course objectives:

  • To understand how to develop a good research question
  • To explore the principles of good trial design
  • To know where to apply for trial funding
  • To understand how to write a successful funding application
  • To know how to effectively cost a trial
  • To understand the role of a Clinical Trials Unit

 

Venue: Botnar Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LF

Target audience: This course is specifically targeted at new investigators who would like to design and conduct their own trial but who have not yet successfully applied for funding.

Cost: £75 

CPD Credits: Approved by the Federation of the Royal College of Physicians for 5 category 1 (external) CPD credit(s)

 

Please note places are limited. Please email octrutrialshub@ndorms.ox.ac.uk for further details.

Similar stories

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.